Determination of short-term myocardial drug uptake and subsequent redistribution was performed in 27 patients with ischemic heart disease for the antiarrhythmic agents lidocaine and mexiletine, using frequent simultaneous measurements of drug concentration in aortic and coronary sinus blood, combined with measurement of coronary sinus blood flow after intravenous bolus injection of the drug. Maximal myocardial drug content per unit resting coronary sinus blood flow (MDC:F) was significantly greater in patients in whom coronary sinus pacing at 100 beat/min was performed during the initial period of drug uptake. Maximal myocardial drug content occurred after 2.4 + 0.2 (SEM) for lidocaine and after 5.5 ± 0.6 min for mexiletine (p < .001), and pacing did not affect time to maximum myocardial drug content. In nonpaced, but not paced, patients maximal MDC:F was greater in the lidocaine group than that in the mexiletine group. The subsequent efflux of lidocaine from the myocardium was more rapid that that of mexiletine in both paced and nonpaced groups. Circulation 73, No. 5, 987-996, 1986. From the
THE SHORT-TERM intravenous administration of cardioactive drugs is usually performed with the objective of inducing rapid and reproducible effects, often during a period of hemodynamic instability. In the case of antiarrhythmic drugs, efficacy in reverting tachyarrhythmias is likely to be correlated with drug concentrations within that region of myocardium responsible for arrhythmogenesis, although this hypothesis has never been tested. The electrophysiologic and many of the hemodynamic effects of these agents also probably correlate with drug concentrations within various regions of the myocardium, or mean myocardial con-
centrations.
No previous studies have been able to fully determine the characteristics of short-term myocardial drug uptake in man. Most of the information currently avail-able has been derived from conventional pharmacokinetic studies, which use peripheral venous blood sampling to examine the clearance of drugs from blood or plasma1-3 and rely on the assumption that drug uptake into the myocardium is a component of "central compartment" kinetics.' However, short-term studies correlating electrophysiologic effects of drugs such as procainamide5 and verapamil6 with plasma drug concentrations have served to emphasize the lack of equilibrium between plasma and myocardium under non--steady-state conditions and have raised the possiblity that at least part of the myocardium acts as a "peripheral" compartment of drug uptake despite relatively high global perfusion. 7 We now report the development of a method for the determination of short-term drug uptake in man and of the subsequent pattern of drug efflux from the myocardium. This method has been applied initially to the type IB antiarrhythmic agent lidocaine and to its derivative mexiletine, and offers a potential means of correlating myocardial drug content, drug effects, and the results of conventional pharmacokinetic studies.
Methods
Patients. Patients had classic angina pectoris or atypical chest pain and were undergoing diagnostic cardiac catheterization. Exclusion criteria were unstable angina, coexistent valvular heart disease, severe left ventricular dysfunction, left main coronary artery stenosis, or previous adverse reactions to lidocaine, mexiletine, or bupivacaine. No patient had a history of ventricular or atrial arrhythmias.
Protocol. The investigational protocol and consent form were approved by the Ethics Committe of the Austin Hospital.
Informed consent was obtained before cardiac catheterization.
All previously prescribed antianginal medications were continued up to the time of cardiac catheterization. Local anesthetics used in association with the catheterization procedure were 2% lidocaine for patients subsequently receiving mexiletine and 0.5% bupivacaine for those subsequently receiving lodocaine.
Fifteen minutes after completion of the diagnostic cardiac catheterization and coronary arteriography, a No. 8F coronary sinus thermodilution pacing catheter (Webster Laboratories, Altadena, CA) was inserted into an antecubital vein and advanced under fluoroscopic guidance into the coronary sinus. The catheter was advanced well within the orifice of the coronary sinus to minimize the possibility of significant reflux of right atrial blood; catheter location was confirmed by injection of 3 to 5 ml of radiographic contrast medium. The positions of the patient and catheter were held constant throughout each study, with stable position of the coronary sinus catheter confirmed by fluoroscopy.
Mean and phasic femoral arterial pressure was measured with an arterial sheath.8 Where indicated, No. 7F balloon-tipped catheters were inserted into the main pulmonary artery and No. 7.3F pigtail catheters into the ascending aorta to permit sampling from these sites. An intravenous catheter was inserted into an antecubital vein contralateral to that subsequently used for injection of drugs and was used for subsequent sampling of peripheral venous blood. Femoral arterial blood samples were withdrawn via the previously inserted sheath.
After all catheters had been appropriately placed, coronary sinus blood flow was measured at rest. After a further 2 min, in approximately half the patients, coronary sinus pacing (by electrodes on the coronary sinus catheter) was instituted at 100 beats/min. Coronary sinus blood flow was remeasured in both paced and nonpaced subgroups of patients after a further 2 min.
Immediately after this, a bolus dose of lidocaine (50 mg) or mexiletine (100 mg) was administered intravenously over approximately 10 sec into a peripheral vein and washed through with 20 ml of 5% dextrose. The dosage of drugs used was approximately half that commonly used for routine initial intravenous treatment of tachyarrhythmias and was employed to minimize the possibility of adverse hemodynamic effects while still permitting subsequent determination of drug concentrations in blood. Subsequently, simultaneous blood samples of 2 to 5 ml were drawn at regular intervals from various sites. In most experiments, these were femoral artery, coronary sinus, femoral vein, and peripheral vein. Central aortic and pulmonary samples were taken in some preliminary experiments. Sampling was carried out at 30 sec intervals for 3 min and repeated at 4, 5, 10, 15, 10, 20, and 30 min after drug injection. For patients receiving lidocaine, additional femoral arterial samples were drawn 15 and 45 sec after drug injection. Coronary sinus pacing was terminated 2 min after drug injection. Coronary sinus blood flow was measured routinely 3, 7, 12, 18, 25, and 30 min after injection. Heart rate, electrocardiogram, and femoral arterial pressure were monitored throughout. All central catheters were removed after 30 min, but prolonged peripheral venous sampling was continued to permit characterization of the pharmacokinetic profile of the drugs administered.
Whole blood concentrations of lidocaine and mexiletine were measured by high-performance liquid chromatographic assays similar to previously described methods,9' 1 with threshold sensitivities for drug detection of 10 ng/ml. Although both assays can be used to detect the metabolites of each drug, all metabolite concentrations remained below the detection threshold throughout this study. Data analysis. Coronary sinus blood flow (F) was calculated by the method of Ganz et al.11:
where TM = temperature of blood-injectate mixture, TI = temperature of the 5% dextrose-water injectate, TB = temperature of blood, K = constant of specific heat, and Q = infusion rate of injectate (36 ml/min). Changes in Q between measurements periods were assumed to be linear, and from this Q was calculated for any particular sampling period.
Preliminary experiments examining simultaneous central aortic and femoral arterial drug concentrations demonstrated no significant differences at any time. Therefore, in routine experiments femoral arterial drug concentration was taken as identical to that in blood entering the coronary circulation. Transcoronary drug concentration gradient (8C) was taken as the difference between femoral arterial and coronary sinus drug concentrations, and instantaneous rates of myocardial drug uptake (MDU) or mean rates over more prolonged periods were calculated from the formula: MDU = 8C * F.
Myocardial drug content (MDC) was calculated for that region of myocardium drained by the coronary sinus from cumulative MDU data, using the formula:
where MDC1 = myocardial drug content at end of previous sampling period, MDU1 and MDU2 = instantaneous myocardial drug uptake at beginning and end of current sampling periods, and t = duration of current sampling period.
Because of variability in the position of the coronary sinus catheter in different patients, the proportion of left ventricular myocardium from which efferent blood was sampled varied appreciably between subjects. By means of the relationship between mass of viable myocardium and resting coronary blood flow, we sought to minimize the impact of this variability by also determining myocardial drug content per unit resting coronary sinus flow (MDC:F). MDC:F was usually expressed as a percent of injected drug dose to facilitate comparison of data for lidocaine and mexiletine.
Conventional pharmacokinetic analysis was carried out in peripheral blood samples, with elimination half-life being determined by a least-squares regression method. Transfemoral drug concentration gradient was determined by comparison of femoral arterial and venous drug concentrations, while paired pulmonary arterial and aortic concentrations were used to measure short-term drug uptake within the pulmonary vascular bed.
Statistical analysis. Comparisons of groups of data were made by unpaired twotailed t tests. For comparisons of multiple groups of data, initial assessment was by analysis of variance. Whenever such analysis indicated the presence of significant intergroup variability, subsequent comparisons between groups were performed by unpaired two-tailed t tests. To determine the significance of changes in coronary sinus blood flow induced by atrial pacing, Dunnett's t test was used to compare flow determinations in the peripacing period with control flow measurements. Results are expressed throughout as mean ± SEM.
Results
Clinical data. The clinical features and diagnostic catheterization data of the patients are summarized in 14 of these patients (during pacing in eight cases) and mexiletine to 13 (during pacing in six cases). Although there were no major differences in the clinical features of the various subgroups of patients, the mean age of the mexiletine pacing group was somewhat lower than that of the other three groups. Fifteen patients were currently receiving treatment with /8-adrenoceptor antagonists, 13 with calcium antagonists, and eight with long-acting nitrate preparations. The mean extent of coronary artery dis-ease was less in the lidocaine nonpacing subgroup than that in other subgroups. Left (lidocaine in one case, mexiletine in three) into a peripheral vein. The findings that femoral arterial lidocaine concentrations fluctuated very rapidly during the first minute after administration led to the adoption of the practice of sampling at 15 sec intervals to minimize errors. No significant difference was found between whole blood drug concentrations from any of these sampling sites over the first 15 min after drug injection. It was therefore concluded that drug concentrations in femoral arterial blood were virtually identical to those simultaneously present in the ascending aorta and thus could be taken as representative of concentrations of drugs entering the coronary circulation.
The lack of consistently detectable drug concentration gradients between pulmonary artery and aorta was expected from previous experiments, 12 which suggested that the mean duration of net uptake of many drugs into the lung is extremely short. As a consequence, pulmonary uptake of both lidocaine and mexiletine could not be quantitated by the current methods.
Coronary sinus blood flow. Changes in coronary sinus blood flow during the course of the experiment are depicted in figure 1 . Resting coronary sinus flow was somewhat lower for the lidocaine pacing subgroup than that for the other three subgroups, although this difference was not statistically significant. Coronary sinus pacing during the initial period of the protocol was associated with a minor increase in coronary sinus blood flow, which was statistically significant for patients receiving mexiletine (p < .05) but not for those receiving lidocaine. The small increase in coronary sinus blood flow with pacing in the latter subgroup may have reflected decreased coronary vasodilator reserve.
Myocardial drug uptake. For both lidocaine and mexiletine, detectable concentrations of drugs were present in femoral arterial blood within 0.5 min of drug injection and in coronary sinus blood within 0.5 to 2.5 min of injection. In all cases, initial femoral arterial drug concentrations exceeded coronary sinus concentrations, indicating a period of net drug uptake by the myocardium. Thereafter, transcoronary drug concentration gradients gradually reduced, with eventual reversal of concentration gradient, indicating a period of net drug efflux from the myocardium.
The time course of femoral arterial and coronary sinus concentrations of lidocaine and mexiletine is compared in figures 2 and 3. The initial period of net drug uptake was more transient for patients receiving lidocaine than for those receiving mexiletine and did not appear to be affected by initial pacing. The persistance of significant coronary sinus-femoral arterial concentration gradients to the end of the sampling period (30 min) indicates continued drug efflux at least for this period of time ( figure 3) .
The time course, as well as the extent of myocardial drug uptake, varied both between patients receiving lidocaine and mexiletine and between paced and nonpaced subgroups. Comparisons of the extent of myocardial drug uptake between patients receiving lidocaine and mexiletine were made by expressing uptake as a percentage of injected drug dose, assuming that dose-dependent uptake did not occur. (Two experiments were carried out with double-dose injections of lidocaine and mexiletine and did not suggest nonlinearity of uptake mechanisms.)
The time course of MDC:F is plotted on this basis for the various subgroups in was significantly greater in the paced than in the nonpaced subgroups for both lidocaine (p < .05) and mexiletine (p < .01). Although maximal MDC:F was somewhat higher for patients receiving lidocaine than for those receiving mexiletine, this difference was statistically significant only in the nonpaced subgroups (p <.01). In individual patients, the mean time to maximal MDC was 2.4 + 0.2 min (range 1.5 to 4.0) for lidocaine and 5.5 ± 0.6 min (range 3.0 to 10.0) for mexiletine (p < .001). There was no significant difference between times to maximal MDC between the paced and nonpaced subgroups for either drug. Maximal MDC:F was 20.7 + 4.5 and 14.2 + 1.2 for the paced and nonpaced lidocaine subgroups (p = NS) and 15.6 + 1.5 and 8.5 + 1.2 for the paced and nonpaced mexiletine subgroups (p < .05).
No correlation was found between the time to maximum MDC or maximal MDC:F and either cardiac index or the extent of fixed coronary artery stenoses for any subgroup of patients.
The rates of decline of myocardial drug content, while apparently independent of prior pacing, varied widely between drugs. Decline in calculated myocardial lidocaine concentration during the 30 min study period was apparently biphasic, while that of mexiletine was monophasic ( figure 4 ). Twenty-five minutes after drug injection, mean residual myocardial lidocaine content was 28 ± 6% and mexiletine content was 62 6% of maximal value (p < .0 1). Plasma elimination half-lives of lidocaine and mexi- THERAPY AND PREVENTION-PHARMACODYNAMICS continued for a considerably longer period than uptake into the myocardium.
Discussion
The results of these experiments establish for the first time that coronary sinus catheterization can be used to characterize the process of short-term drug uptake into the human myocardium, as well as the pattern of subsequent drug efflux from the heart. Previous investigators have developed a number of techniques suitable for performing similar determinations in animal studies. These have included the use of direct myocardial biopsy with a high-speed boring tool,13 which, while yielding considerable information about myocardial concentration after short-term bolus or infusion of a number of drugs,'3-16 is obviously not suitable for serial studies in man. Moreover, the combination of such investigations with the use of radiolabeled injected drug17-19 is a less acceptable technique for use in man.
However, studies of myocardial drug handling in intact animals as well as in isolated tissues have proved particularly useful for elucidating general principles involved. It has emerged that a large number of factors combine to determine myocardial drug concentration. These include the lipid solubility of the drug concerned,'3' 20, 21 regional myocardial blood flow,22 23 and general hemodynamic status.'7 In the case of digoxin, increased myocardial mechanical activity was associated with an increase in myocardial drug concentration 1 hr after intravenous injection, but this increase was apparently independent of associated coronary vasodilation. 18 Less information is available on the factors determining drug washout from the myocardium. In monolayers of chick embryo ventricular cells, the duration of action of initially equieffective concentrations of various calcium antagonists varied widely, correlating roughly with their relative plasma half-lives and suggesting considerable variability in affinity of tissue binding.24 However, in most other animal preparations of cardiac drug effect in vitro, drug washout has not been closely studied, despite the potential importance of this process as a determinant of duration of drug effect. The major technical difficulty associated with such studies is prolonged myocardial binding of many cardioactive drugs, such as amiodaronel5; washout is more easily assessed in agents for which the affinity of tissue binding is less marked, such as propranololl3 or lidocaine. 25 Previous studies in man, as well as in intact animal preparations, have suggested that during short-term Vol. 73, No. 5, May 1986 drug administration correlations between peripheral venous drug concentrations and cardiac drug effects are often poor. This lack of equilibration is reflected in a "hysteresis effect" when comparisons are made during drug loading and washout for both procainamide26 and verapamil27 and identifies the need to be able to correlate effects with myocardial drug content.
Myocardial biopsy has been possible in patients undergoing cardiac surgery, 2 2' but is is not readily applicable to evaluation of short-term drug use. Furthermore, the institution of cardiopulmonary bypass may alter pharmacokinetics from their previous steady state. 30 In three studies3'"3 attempts were made to measure short-term myocardial drug uptake in man by means of coronary sinus catheterization, but these studies were limited by factors such as lack of determination of coronary blood flow, inadequate frequency of sampling during the initial period after drug injection, assay of drug concentrations in plasma rather than whole blood, and the use of an initial period of drug infusion rather than bolus injection. Two of these studies31' 32 examining the uptake characteristics of ouabain indicated widely disparate mean durations of net myocardial uptake: approximately 431 and 20 min,32 respectively. Neither study was able to document a subsequent phase of net drug efflux from the myocardium. On the other hand, Hayward et al. ' using initial drug infusion over 5 min and initial blood sampling 10 min after cessation of infusion, were able to demonstrate only the efflux phase of methyldigoxin, the uptake phase being by inference less than 15 min in duration. In the currently reported experiments, care was taken to avoid these problems. The two drugs studied had no detected coronary or systemic hemodynamic effects in the doses used. The absence of major hemodynamic effects combined with rapid time course of short-term myocardial drug uptake has been anticipated as suitable characteristics for drugs to be studied initially with this method. Because of initially rapid changes in drug concentration, especially in arterial blood, a high frequency of sampling was used during the initial 3 min after drug injection. Changes in catheter position during the experimental protocol were carefully avoided. The possibility of reflux of blood from the right atrium into the coronary sinus,3 which would have caused potential underestimation of transcoronary drug concentration gradients, was minimized by positioning the coronary sinus catheter well within the orifice of the coronary sinus. This precaution probably resulted in underestima-tion of coronary sinus blood flow in many patients because of entry of terminal tributaries of the coronary sinus beyond the tip of the catheter. In view of this limitation, and because not all coronary blood flow drains into the coronary sinus, it is appropriate to regard individual determinations of myocardial drug uptake as being representative only of uptake into a part of the myocardium. The determination of MDC:F therefore provided a useful means of minimizing the impact of interpatient variation in catheter placement on assessment of cardiac drug uptake. The finding of an initial phase of net drug uptake into the myocardium, followed by one of net efflux, is in accordance with the results of previous animal experiments for other agents' 1-6 and with previous preparations of the initial tissue distribution of lidocaine. '6 In the case of lidocaine, the initial period of net uptake was more transient than that for mexiletine and was also somewhat more extensive. In each case the mean period of net drug uptake was considerably shorter than that predicted on the basis of the "distribution" half-life, as previously determined by conventional pharmacokinetic methods. 37 38 If the differences between global myocardial uptake characteristics of lidocaine and mexiletine are major determinants of differences in their short-term efficacy, these findings would imply that lidocaine may be a more suitable agent for the initial emergency management of ventricular tachyarrhythmias. However, it remains possible that drug uptake into poorly perfused, arrhythmogenic regions of myocardium is slower than global uptake. Moreover, antiarrhythmic drug effects may relate to drug concentration at the cell surface, whereas intracellular drug concentrations may rise more slowly.2' Subsequent studies, examining correlations between global myocardial drug content and drug effects, are needed to elucidate this area.
Coronary sinus pacing at 100 beats/min during the initial period after drug injection induced an increase in maximal MDC, which was more marked in the case of mexiletine. This is consistent with the results of Lull- Taylor. 18 The somewhat greater increment in myocardial drug uptake of mexiletine induced by pacing is consistent with the results of Lullman et al.,39 who observed that effects of pacing on uptake were more marked for slowly than for rapidly equilibrating drugs. Extensive myocardial ischemia probably did not occur during this relatively brief and mild pacing period but might have been an important factor if prolonged pacing at a higher rate had been used. The marked increment in myocardial uptake of mexiletine with pacing may partially explain the apparently greater efficacy of this and other type I antiarrhythmic drugs in the shortterm treatment rather than long-term prophylaxis of ventricular tachycardia.40 '4 It was also possible to define a period of net drug efflux from the myocardium for both lidocaine and mexiletine. For both drugs, the initial rate of drug efflux was considerably more rapid than the elimination half-life, as determined by conventional pharmacokinetic methods. Thus drug metabolism is unlikely to have contributed significantly to the observed efflux phase. Rather, efflux represented a period of redistribution of drugs to other tissues, possibly less well perfused than myocardium but with a high capacity for drug uptake. 35' 36 The persistence of a continued arteriovenous drug concentration gradient within the femoral vascular bed throughout the experiment suggests that skeletal muscle may be one site of redistribution for both lidocaine and mexiletine.
The rates of lidocaine and mexiletine efflux from the myocardium, although not identical to simultaneous changes in peripheral venous drug concentrations, appear to be well correlated with the relative durations of action of these agents.4> Mexiletine efflux was slow and apparently monophasic, whereas lidocaine efflux was relatively rapid and biphasic, with mean residual myocardial drug concentrations of only 28 ± 6% 25 min after drug injection.
A number of potential limitations of the current study are worthy of mention. It is possible, although unlikely, that myocardial uptake of lidocaine and/or mexiletine is readily saturable and therefore that the results of these experiments cannot be extrapolated to other drug doses. Furthermore, the uptake characteristics of the drugs under investigation may have been affected by other agents, such as the local anesthetics used at the time ofcatheter placement,45 via competition for binding sites on plasma proteins or within the myocardium. In individual patients, errors in estimation of transcoronary drug uptake may have been induced by undetected fluctuations in coronary sinus blood flow.
Finally, the method, as currently used, yields information concerning drug handling by a segment of the left ventricle rather than total myocardial drug uptake or uptake into the major sites of drug action.
Despite these limitations, the reported technique has a number of unique advantages for studying drug effects in man. It should now be possible to examine correlates between myocardial drug content and shortterm drug effect for antiarrhythmic and inotropically active agents. This may of of particular value in the interpretation of short-term responses to antiarrhythmic agents during electrophysiologic study. It may also be possible to extrapolate from short-term drug uptake to predict steady-state myocardial drug concentration and drug effects on the myocardium and thus to improve both understanding and efficacy of utilization of cardioactive drugs.
